# US 10,245,428 B2 · Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,245,428 B2 - Document ID: US10245428B2 - Status: Granted - Kind: B2 - Application number: 15/239,759 - Filed: 2016-08-17 - Published: 2016-12-22 - Granted: 2019-04-02 - Earliest claimed: 2009-02-12 - Assignees: InCube Labs, LLC - Applicants: InCube Labs, LLC - Inventors: Mir Imran - Web page: https://patentgrep.com/patent/US10245428B2 ## CPC - A61N 1/325: {for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body (electrodes for external use A61N1/0428)} - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil - A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl - A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam - A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid - A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine - A61K 33/00: Medicinal preparations containing inorganic active ingredients - A61K 33/26: Iron; Compounds thereof - A61K 38/26: Glucagons - A61K 38/28: Insulins - A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent} - A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) - A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04) - A61N 1/0448: {Drug reservoir} - A61M 2037/0007: {having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents} - A61N 1/30: Apparatus for iontophoresis, {i.e. transfer of media in ionic state by an electromotoric force into the body}, or cataphoresis - A61N 1/327: {for enhancing the absorption properties of tissue, e.g. by electroporation} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} ## Abstract An embodiment of a system includes a power source and at least two electrode assembles. The power source that an output current that alternates between a maximum current value and a minimum current value; a pair of electrode assemblies. Each electrode assembly is configured to be held in contact with a skin layer of a user. Additionally, each electrode assembly includes an electrode that is coupled to the power source to receive the output current from the power source. At least one of the electrode assemblies in the pair includes a medium that carries an active agent having a charge, the medium being provided on the at least one electrode assembly to enable the output current to repel the active agent into the skin layer for a duration in which the output current has a polarity that is the same as a polarity of the active agent. ## Claims ### Claim 1 A system for transdermal delivery of active agents for therapeutic and medicinal purposes, the system comprising: a power source that generates a charged balanced alternating output current that varies between a first current value and a second current value; a pair of electrode assemblies comprising a first electrode assembly and a second electrode assembly, each electrode assembly applied to a corresponding skin layer of a user, and wherein each electrode assembly includes an electrode that is coupled to the power source to receive the output current; an operative interface coupled to the power source, the operative interface being configured to cause the power source to provide output current to the pair of electrode assemblies based on input detected from one or more sensors provided with the user; and wherein at least one of the electrode assemblies in the pair includes a contact thickness configured to carry an active agent having a charge, the contact thickness being provided on the at least one electrode assembly to enable a corresponding received output current to alternatively repel the active agent into the skin layer from the at least one electrode assembly for a duration in which the output current has a polarity that is the same as a polarity of the active agent, wherein the operative interface, based on the detected input from the one or more sensors, causes the power source to provide output current to the at least one electrode assembly corresponding to (i) a delivery mode in which the output current has the polarity that is the same as the polarity of the active agent, or (ii) a non-delivery mode in which the output current has the polarity that is opposite from the polarity of the active agent. ### Claim 2 (depends on 1) The system of claim 1, wherein the contact thickness includes the active agent and the agent is one of a drug, an antibiotic, an anti-diarrheal agent, an insulin compound, or a vaccine. ### Claim 3 (depends on 1) The system of claim 1, wherein the contact thickness includes the active agent and the agent includes a selected amount of iron. ### Claim 4 (depends on 1) The system of claim 1, wherein, in the non-delivery mode, the output current maintains the at least one electrode assembly in a deployed state but retains the active agent with the at least one electrode assembly as a result of a polarity of the active agent. ### Claim 5 (depends on 1) The system of claim 1, wherein each of the at least one electrode assembly further includes a re-sealable intake conduit formed upon a surface of the electrode assembly, the re-sealable intake conduit configured to permit refill of the contact thickness. ### Claim 6 (depends on 5) The system of claim 5, wherein the at least one electrode assembly including the re-sealable intake conduit is constructed to be reusable. ### Claim 7 (depends on 6) The system of claim 6, wherein the re-sealable intake conduit includes a self-sealing port that enables the active agent to be readily dispersed in the contact thickness. ### Claim 8 (depends on 1) The system of claim 1, wherein each of the at least one electrode assembly including the contact thickness further includes a tissue contacting porous layer configured to absorb the active agent from the contact thickness and introduce the active agent upon the skin layer. ### Claim 9 (depends on 8) The system of claim 8, wherein the tissue contacting porous layer has a selected porosity based on a molecular characteristic of the active agent. ### Claim 10 (depends on 1) The system of claim 1, wherein the one or more sensors collect data related to a physiological condition of the user and transmit the data to the operative interface. ### Claim 11 (depends on 1) The system of claim 1, wherein the operative interface includes logic to determine a presence or an absence of a physiological condition of the user based on the detected input from the one or more sensors, wherein the presence of the physiological condition triggers the delivery mode, and the absence of the physiological condition triggers the non-delivery mode. ### Claim 12 An electrode assembly for delivery of active agents, the assembly comprising: a power connector coupled to a power source that generates a charged balanced alternating output current that varies between a first current value and a second current value, the power source further coupled to a second electrode assembly applied to a skin layer of a user and an operative interface, the operative interface being configured to cause the power source to provide output current to the electrode assembly based on input detected from one or more sensors provided with the user; a tissue contacting layer applied to the skin layer of the user; an electrode, coupled to the power source, to receive the output current; and wherein the electrode includes a contact thickness that carries an active agent having a charge, the contact thickness being provided on the electrode to enable a received output current to alternatively repel the active agent into the skin layer from the electrode assembly for a duration in which the output current has a polarity that is the same as a polarity of the active agent, wherein the operative interface, based on the detected input from the one or more sensors, causes the power source to provide output current to the electrode corresponding to (i) a delivery mode in which a duration in which the output current has the polarity that is the same as the polarity of the active agent, or (ii) a non-delivery mode in which the output current has the polarity that is opposite from the polarity of the active agent. ### Claim 13 (depends on 12) The assembly of claim 12, wherein the active agent is one of a drug, an antibiotic, an anti-diarrheal agent, an insulin compound, or a vaccine. ### Claim 14 (depends on 12) The assembly of claim 12, wherein the active agent includes a selected amount of iron. ### Claim 15 (depends on 12) The assembly of claim 12, wherein, in the non-delivery mode, the output current maintains the at least one electrode assembly in a deployed state but retains the active agent with the at least one electrode assembly as a result of a polarity of the active agent. ### Claim 16 (depends on 12) The assembly of claim 12, further comprising a re-sealable intake conduit formed upon a surface of the electrode assembly, the re-sealable intake conduit configured to permit refill of the contact thickness. ### Claim 17 (depends on 16) The assembly of claim 16, wherein the assembly, including the re-sealable intake conduit, is constructed to be reusable. ### Claim 18 (depends on 17) The assembly of claim 17, wherein the re-sealable intake conduit includes a self-sealing port that enables the active agent to be readily dispersed in the contact thickness. ### Claim 19 (depends on 12) The assembly of claim 12, wherein the one or more sensors collect data related to a physiological condition of the user and transmit the data to the operative interface. ### Claim 20 (depends on 12) The assembly of claim 12, wherein the operative interface includes logic to determine a presence or an absence of a physiological condition of the user based on the detected input from the one or more sensors, wherein the presence of the physiological condition triggers the delivery mode, and the absence of the physiological condition triggers the non-delivery mode.